3DD1

Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254

Summary for 3DD1

• Entry DOI: 10.2210/pdb3dd1/pdb
• Related: 3DDS 3DDW
• Descriptor: Glycogen phosphorylase, liver form, N-acetyl-beta-D-glucopyranosylamine, PYRIDOXAL-5'-PHOSPHATE, ... (8 entities in total)
• Functional Keywords: glycogen phosphorylase hlgp, diabetes, allosteric enzyme, carbohydrate metabolism, disease mutation, glycogen metabolism, glycogen storage disease, glycosyltransferase, nucleotide-binding, phosphoprotein, pyridoxal phosphate, transferase
• Biological source: Homo sapiens
• Total number of polymer chains: 2
• Total formula weight: 197988.36

Authors

Nolte, R.T. (deposition date: 2008-06-04, release date: 2009-04-21, Last modification date: 2023-08-30)

• Primary citation: Thomson, S.A.,Banker, P.,Bickett, D.M.,Boucheron, J.A.,Carter, H.L.,Clancy, D.C.,Cooper, J.P.,Dickerson, S.H.,Garrido, D.M.,Nolte, R.T.,Peat, A.J.,Sheckler, L.R.,Sparks, S.M.,Tavares, F.X.,Wang, L.,Wang, T.Y.,Weiel, J.E.; Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.; Bioorg.Med.Chem.Lett., 19:1177-1182, 2009; PubMed: 19138846; DOI: 10.1016/j.bmcl.2008.12.085

Experimental method

X-RAY DIFFRACTION (2.57 Å)